EcoDrugPlus

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSLCAG00010000951
Gene Symbol: MAPK3
4 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSLCAG00010003734
Gene Symbol: MAPK8A
4 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSLCAG00010022430
Gene Symbol: MAPK8B
1 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSLCAG00010004614
Gene Symbol: MAPK9
1 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSLCAG00010011873
Gene Symbol: LOC108886445
4 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSLCAG00010006202
Gene Symbol: MAP2K2A
4 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSLCAG00010016500
Gene Symbol: MAP2K2B
4 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSLCAG00010006587
Gene Symbol: MAP3K10
1 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSLCAG00010010208
Gene Symbol: MAP3K11
2 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLCAG00010017038
Gene Symbol: MAP3K12
2 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLCAG00010020637
Gene Symbol: MAP3K12
4 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSLCAG00010022673
Gene Symbol: MAP3K13
2 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).